Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Gourni

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current ProgressSurachet Imlimthan, Euy Sung Moon, Hendrik Rathke, et al.
Nuclear Medicine and Biology|May 1, 2014
PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonistsMazen Jamous, Maria L Tamma, Eleni Gourni, et al.
Bioorganic & Medicinal Chemistry|March 27, 2012
Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceuticalDimitrios Psimadas, Melpomeni Fani, Eleni Gourni, et al.
Molecular Imaging|November 4, 2017
Radiochemistry and Preclinical PET Imaging of <sup>68</sup>Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane AntigenEleni Gourni, Luigi Del Pozzo, Mark Bartholomä, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 20, 2019
Dynamic patterns of [<sup>68</sup>Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesionsIan Alberts, Christos Sachpekidis, Eleni Gourni, et al.
Nuclear Medicine and Biology|November 21, 2016
Approaches to improve metabolic stability of a statine-based GRP receptor antagonistIlinca Popp, Luigi Del Pozzo, Beatrice Waser, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Preclinical Evaluation of a <sup>177</sup>Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with EverolimusNaveen Kumar, Adrianna Bilinska, Elena Menéndez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 17, 2025
Preclinical evaluation of DOTAGA.Glu.(FAPI)<sub>2</sub> and DO3A.Glu.(FAPI)<sub>2</sub> as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogsAdrianna Bilinska, Naveen Kumar, Silvano Gnesin, et al.
Anticancer Research|February 16, 2006
Evaluation of a series of new 99mTc-labeled bombesin-like peptides for early cancer detectionEleni Gourni, Maria Paravatou, Penelope Bouziotis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 23, 2014
N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imagingEleni Gourni, Rosalba Mansi, Mazen Jamous, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current ProgressSurachet Imlimthan, Euy Sung Moon, Hendrik Rathke, et al.
Nuclear Medicine and Biology|May 1, 2014
PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonistsMazen Jamous, Maria L Tamma, Eleni Gourni, et al.
Bioorganic & Medicinal Chemistry|March 27, 2012
Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceuticalDimitrios Psimadas, Melpomeni Fani, Eleni Gourni, et al.
Molecular Imaging|November 4, 2017
Radiochemistry and Preclinical PET Imaging of <sup>68</sup>Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane AntigenEleni Gourni, Luigi Del Pozzo, Mark Bartholomä, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 20, 2019
Dynamic patterns of [<sup>68</sup>Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesionsIan Alberts, Christos Sachpekidis, Eleni Gourni, et al.
Nuclear Medicine and Biology|November 21, 2016
Approaches to improve metabolic stability of a statine-based GRP receptor antagonistIlinca Popp, Luigi Del Pozzo, Beatrice Waser, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Preclinical Evaluation of a <sup>177</sup>Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with EverolimusNaveen Kumar, Adrianna Bilinska, Elena Menéndez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 17, 2025
Preclinical evaluation of DOTAGA.Glu.(FAPI)<sub>2</sub> and DO3A.Glu.(FAPI)<sub>2</sub> as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogsAdrianna Bilinska, Naveen Kumar, Silvano Gnesin, et al.
Anticancer Research|February 16, 2006
Evaluation of a series of new 99mTc-labeled bombesin-like peptides for early cancer detectionEleni Gourni, Maria Paravatou, Penelope Bouziotis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 23, 2014
N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imagingEleni Gourni, Rosalba Mansi, Mazen Jamous, et al.
Pageof 4